Board of Directors
Associate Professor Mark Kirkland – Medical Director
Mark is Associate Professor at the Institute of Technology, Research and Innovation at Deakin University.
He is a specialist haematologist with more than 25 years research experience in the field of haemopoietic stem cell biology and 15 years’ experience as a clinical and laboratory haematologist.
A former Medical Director of Research for the Australian Red Cross Blood Service in Victoria, he has extensive experience in blood and tissue banking, both public and private cord blood banking, and bone banking.
He was also a member of the committee that developed the Australian (NPAAC) Guidelines for Haemopoietic Stem Cells.
Mark is the Chief Scientific Officer of Cytomatrix Pty Ltd, a biotechnology company specialising in novel technologies for the growth and expansion of cord blood stem cells.
His current research interests include:
- Cord blood stem cell expansion
- The clinical use of cord blood in the treatment of cerebral palsy and type 1 diabetes.
Associate Professor Kirkland has been instrumental in the design and development of Cell Care's Clinical Trial program, and in particular has instigated the proposed Australia-wide trial in the use of cord blood to prevent the progression of type 1 diabetes.
Brent Dennison - Chief Executive Officer
Brent was most recently involved in the launch of Mothercare in Australia, and was CEO of that business until June 2012. Prior to that, Brent worked in Europe in the private equity industry for 6 years, focusing on growth opportunities and international expansion. Before moving to Italy, Brent was a director with Citigroup in New York investing in growth financial services businesses of strategic interest to the bank. Ahead of joining Citigroup, Brent led two entrepreneurial ventures; a UK-based software business and the launch of Turkey's first management consulting practise in the late 1990s. Before embarking on entrepreneurial pursuits, Brent was a strategy consultant with the Boston Consulting Group in Melbourne and New York.
Jim Craig - Chairman
After working as a lawyer in Australia and Japan, Jim joined Macquarie Group Limited. He held a number of senior roles within Macquarie in the resources, infrastructure and fund management areas, including leading Macquarie’s businesses in Europe from 2003–08 and was Chairman of Macquarie Capital (Melbourne) from 2008-14.
Jim is also a Director of the following:
- Australian Super – Board member and Chairman, Australian Super Investment Committee
- Australian United Investment Company Limited - Chairman, Nomination & Remuneration Committee
- River Capital Pty Ltd - Executive Chairman
- Lifestyle Communities Limited - Chairman, Nomination & Remuneration Committee
- UHG – Board member
Jim also has a portfolio of investments in other listed and private companies.
Glenn Kerkhof - Non-Executive Director
Glenn Kerkhof was appointed non-executive director of Cell Care Australia Pty Ltd in March 2015.
Glenn has over 22 years’ experience in the contract research or drug development industry. Glenn is the Executive Chairman of George Clinical, a leading Asian contract research organisation. Prior to joining George Clinical he was the Chief Executive Officer at Chiltern International, a global CRO based in London. Glenn also served as Vice President, Clinical Services for Charles River Laboratories and as Vice President, Clinical Europe for Inveresk Research.
Glenn is a non-executive director of Immunoglobal Pty. Ltd. He holds a Bachelor of Commerce from Deakin University (Australia) and a Masters of Business Administration from the University of Edinburgh (UK).
Dianne Lucas - Director
Dianne devotes most of her time to her philanthropic pursuits with a passion for medical research, animal welfare, human rights and the arts. Her major focus is ethics.
Amongst other things she is currently Chair of the Lort Smith Animal Hospital Ethics Committee, Chair of the Healthy Women's, Healthy Babies Fundraising Committee for The Burnet Institute and a Patron of the Arts actively supporting the MSO and The Melbourne Theatre Company.